Mydecine Unveils Artificial Intelligence Drug Discovery Program

Cybin Selects Anxiety Disorder Indications for Proprietary Psychedelic Molecule CYB004

Bright Minds Biosciences Announces Application to List on Nasdaq

Whole-Body Effects of Psychedelics – Part 1

Optimi Health Completes Pre-Clinical Trial Application Meeting

PharmaTher Files FDA Pre-IND Meeting Request and Briefing Package For KETABET™...

Field Trip Health Ltd. Announces Completion of DMPK Studies, Engineering Batch...

PT248 – Pierre Bouchard – Somatic Therapy, Trauma, and the Nervous...

Psychedelic Research Bulletin: May 2021

Psychedelic Bulletin: MindMed CEO Steps Down; Atai Targets $2.3bn Valuation

Load more